---
title: "Kairos Pharma, Ltd. (KAPA.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/KAPA.US.md"
symbol: "KAPA.US"
name: "Kairos Pharma, Ltd."
industry: "Biotechnology"
---

# Kairos Pharma, Ltd. (KAPA.US)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Location | US Market |
| Website | [kairospharma.com](https://kairospharma.com) |

## Company Profile

Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The company develops KROS 101, an orally available g...

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -2.29 | 269/604 | - | - | - |
| PB | 1.52 | 135/604 | 4.05 | 2.42 | 1.68 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2025-11-19T05:00:00.000Z

Total Analysts: **3**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 2 | 67% |
| Overweight | 1 | 33% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 0.57 |
| Highest Target | 12.00 |
| Lowest Target | 4.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/KAPA.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/KAPA.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/KAPA.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.